Search

Displaying results 9351 - 9360 of 10000 in total
  1. Drug

    Oxyphenisatin

    go.drugbank.com/drugs/DB04823
    ApprovedWithdrawn

    A laxative that undergoes enterohepatic circulation. It may cause jaundice.

    Synonyms: 3,3-Bis(p-hydroxyphenyl)oxindole, 3,3-Bis(p-hydroxyphenyl)-2-indolinone
  2. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  3. Drug

    Vatalanib

    go.drugbank.com/drugs/DB04879
    Investigational

    Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors.

  4. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritab...

  5. Drug

    Tamibarotene

    go.drugbank.com/drugs/DB04942
    Investigational

    Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL).

  6. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation.

  7. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET).

  8. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.

  9. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  10. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process.